A Review of Inflammatory Markers in Metabolic Syndrome

Life Sciences-Medicine

Authors

  • Dr.T.M.J.Santhosha kumari Associate Professor, Dept of Biochemistry, Mahatma Gandhi Medical College and Research Institute Sri Balaji Vidyapeeth(deemed to be university) Pillaiyarkuppam, Puducherry, India.
  • Dr.G.Revathy Assistant Professor, Dept of Biochemistry, Mahatma Gandhi Medical College and Research Institute Sri Balaji Vidyapeeth(deemed to be university Pillaiyarkuppam, Puducherry, India
  • Dr.Prabha Associate Professor, Dept of Microbiology, Vels Medical College and Hospital, Chennai, Tamilnadu, India

DOI:

https://doi.org/10.22376/ijlpr.2023.13.2.SP2.L159-L165

Keywords:

Metabolic syndrome (MetS), pro-inflammatory, Cardiovascular Disease (CVD), Serum homocysteine, Triglycerides (TAG)

Abstract

The conditions included in the definition of metabolic syndrome typically include central obesity (excessive fat accumulation around the waist), insulin resistance, hyperglycemia (elevated blood sugar levels), dyslipidemia (abnormal levels of lipids in the blood), and hypertension (high blood pressure). Having any three or more of these conditions is considered to be indicative of metabolic syndrome. Metabolic syndrome (MetS) is emerging as a major public health problem with pro-inflammatory changes leading to Insulin Resistance and Cardiovascular Disease (CVD) at a very young age. Metabolic syndrome (MetS) is a global health concern; metabolic syndrome is becoming more common in our country. It is found to be a risk factor for insulin resistance and abnormal adipose tissue . Clinical symptoms of the syndrome could include abdominal obesity, hypertension, diabetes, hypertriglyceridemia, and low HDL cholesterol. So far various studies have been conducted on the effect of inflammatory markers like Serum Uric acid (UA), serum homocysteine, Leptin, Lp(a) etc. Most of them have reported a positive correlation between these inflammatory markers and the various components of (MetS) like abdominal obesity, elevated Blood pressure, Fasting blood Glucose and Lipid profile abnormalities like elevated Triglycerides (TAG) and low High Density Lipoprotein-Cholesterol (HDL-C). Various studies have reported a positive correlation between serum uric acid and Serum Homocysteine and Lp(a) in causing endothelial dysfunction and premature Cardiovascular events. Hence a review of the studies pertaining to the various inflammatory markers was done. There was an association of various inflammatory markers like uric acid, homocysteine, MDA, lipoprotein and others. More awareness must be created even at the high school level regarding the ill effects of sedentary lifestyle the likely hood of metabolic syndrome. An early identification of surging biomarker levels in high-risk children may find new cases at an earlier stage to prevent upcoming diabetes mellitus and its complications. 

References

Kalofoutis C, Piperi C, Kalofoutis A, Harris F, Phoenix D, Singh J. Type II diabetes mellitus and cardiovascular risk factors: current therapeutic approaches. Exp Clin Cardiol. 2007 Spring;12(1):17-28. PMID 18650975.

Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care. 2002;25(10):1790-4. doi: 10.2337/diacare.25.10.1790, PMID 12351479.

Reaven GM. Role of insulin resistance in human disease. Banting lecture. Diabetes. 1988;37(12):1595-607. doi: 10.2337/diab.37.12.1595, PMID 3056758.

kumar P, clark M. Kumar and Clark’s clinical medicine. 6th ed. Macrophages are the main source of resistin and obesity London: Elsevier Publishers; 2005. p. 982-6.

Barbosa MC, Brandão AA, Pozzan R, Magalhães ME, Campana EM, Fonseca FL, et al. Associac¸ão entre ácido úrico e variáveis derisco cardiovascular em uma populac¸ ão não hospitalar. Arq Bras Cardiol. 2011;96(3):212-8. doi: 10.1590/s0066-782x2011005000011, PMID 21271175.

Serpa Neto A, Rossi FM, Valle LG, Teixeira GK, Rossi M. Relation of uric acid with components of metabolic syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects. Arq Bras Endocrinol Metabol. 2011;55(1):38-45. doi: 10.1590/s0004-27302011000100005, PMID 21468518.

Lee CM, Huxley RR, Woodward M, Zimmet P, Shaw J, Cho NH et al. The metabolic syndrome identifies a heterogeneous group of metabolic component combinations in the Asia-Pacific region. Diabetes Res Clin Pract. 2008;81(3):377-80. doi: 10.1016/j.diabres.2008.05.011, PMID 18617286.

Reddy Seshadri V, Suchitra MM, Reddy YM, Reddy Prabhakar E. Beneficial and detrimental actions of free radicals: a review. J Glob Pharm Technol. 2010;2(5):3-11.

de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr. 2012;4(1):12. doi: 10.1186/1758-5996-4-12.

Bengtsson C, Lapidus L, Stendahal C, Waldenstrom J. Hyper uricemia and risk of cardiovascular disease and overall death. Acta Med Scand. 2002;224(6):549-55.

Reungjui S, Roncal CA, Mu W, Srinivas TR, Sirivongs D, Johnson RJ, et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol. 2007;18(10):2724-31. doi: 10.1681/ASN.2007040416, PMID 17855639.

Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287-93. doi: 10.1161/01.HYP.0000072820.07472.3B, PMID 12743010.

Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor- alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409-15. doi: 10.1172/JCI117936, PMID 7738205.

14. Mohanalakshmi T. Sai Ravi Kiran B, Srikumar R,Franklin A, Prabhakar Reddy E. Evaluation of uric acid level, a new biomarker in patients with metabolic syndrome. Res J Pharm Biol Chem Sci. 2016;7(3):2667-74.

Alshehri AM. Metabolic syndrome and cardiovascular risk. J Family Community Med. 2010 May-Aug;17(2):73-8. doi: 10.4103/1319-1683.71987, PMID 21359028.

Rao KSJ, Mukherjee NR, Rao KV. A Survey of diabetes mellitus in rural population of India. Diabetes. 1972;21(12):1192-6. doi: 10.2337/diab.21.12.1192, PMID 4673866.

Murthy PD, Pullaiah B, Rao KV. Survey for detection of hyperglycemia and diabetes mellitus in Tenali. In: Interprint, New-Delhi, editors. Diabetes mellitus in Developing Countries. Bajaj Js; 1984. p. 55.

Govindaraj V, Das AK, Chandrasekar S. Prevalence of diabetes mellitus in a rural population of Pondicherry. J Diabet Assoc India. 1984;24:20.

devi AJM, Sridevi S. Correlation between serum uric acid levels and non HDL cholesterol in type 2 diabetes mellitus- an observational study. Int J Pharm Biol Sci. 2014 Apr;5(2):696-701.

Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009 Sep;32(9):1737-42. doi: 10.2337/dc09-0288, PMID 19549729.

Martin NE, Garcia NV. Hypouricemia and the tubular transport of uric acid. Nefrologia. 2011;31(1):44-50.

Reddy Seshadri V, Suchitra MM, Reddy YM, Reddy Prabhakar E. Beneficial and detrimental actions of free radicals: a review. J Glob Pharm Technol. 2010;2(5):3-11.

de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr. 2012;4(1):12. doi: 10.1186/1758-5996-4-12.

Bengtsson C, Lapidus L, Stendahal C, Waldenstrom J. Hyper uricemia and risk of cardiovascular disease and overall death. Acta Med Scand. 2002;224(6):549-55.

Mohanalakshmi T, Sai Ravi Kiran B, Srikumar R, Franklin A, Prabhakar Reddy E. Evaluation of Uric Acid Level, A New Biomarker In Patients With Metabolic Syndrome, Research Journal of Pharmaceutical, Biological and Chemical Sciences, 7(3), 2016, 2667-2674. 26. Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Con-cin H. The role of serum uric acid as an antioxidant which protects against cancer: a prospective study in more than 28000 old Austrian women, Ann Oncol, 18(11), 2007,1893-1897.

27. Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17(1):24-38. doi: 10.1002/jbt.10058, PMID 12616644.

28. Hikita M, Ohno I, Mori Y, Ichida K, Yokose T, Hosoya T. Relationship between hyperuricemia and body fat distribution. Intern Med. 2007;46(17):1353-8. doi: 10.2169/internalmedicine.46.0045, PMID 17827832.

29. Kim SK, Park YS, Byoun KE. Comparison of the total antioxidant status and usual dietary intake in normal and overweight males, Korean. J Community Nutr. 2000;5(4):633-41.

30. Molnár D, Decsi T, Koletzko B. Reduced antioxidant status in obese children with multi metabolic syndrome. Int J Obes Relat Metab Disord. 2004;28(10):1197-202. doi: 10.1038/sj.ijo.0802719, PMID 15314634.

31. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR. Association between circulating oxidized low density lipoprotein and incidence of the metabolic syndrome. JAMA. 2008;299(19):2287-93. doi: 10.1001/jama.299.19.2287, PMID 18492970.

32. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752-61. doi: 10.1172/JCI21625, PMID 15599400.

33. Shabana S, Sireesha M, Satyanarayana U. Uric acid in relation to type 2 diabetes mellitus associated with hypertension. 2012;6(7):1140-3.

34. Nejatinamini S, Jafari AA, Qorbani M, Nikoohemat S, Kelishadi Roya, Asayesh H et al. Association between serum uric acid level and metabolic syndrome components. J Diabetes Metab Disord. 2015;14:7.

35. Gurusamy N, Vijayaraghavalu S, Alhazzani A, Chandramoorthy HC. The enigma of uric acid in Metabolic Syndrome. Diabesity. 2015;1(3):29-30. doi: 10.15562/diabesity.2015.18.

36. Lee JW, Cho YK, Ryan MC, Kim H, Lee SW, Chang E et al. Serum uric Acid as a Predictor for the Development of non alcoholic Fatty Liver Disease in Apparently Healthy Subjects: A 5-year Retrospective Cohort Study. Gut Liver. 2010;4(3, Sep):378-83. doi: 10.5009/gnl.2010.4.3.378, PMID 20981217.

37. Santhoshakumari TMJ. A study of Anthropometric and Lipid Profile Parameters in Non-Alcoholic Fatty Liver Disease patients attending a Tertiary Care Hospital at Puducherry. IOSR JDMS. 2017;16(1):33-7. doi: 10.9790/0853-1601123337.

38. Santhoshakumari TMJ, Sneha M. Association between abdominal obesity and subclinical hypothyroidism. Biomed Res. 2019;30(5):760-3.

39. Wolk K, Sabat R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17(3):305-17. doi: 10.1007/s11154-016-9381-0, PMID 27554109.

40. Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016;12(12):1299-308. doi: 10.1080/1744666X.2016.1201423, PMID 27322922.

41. Takahashi H, Tsuji H, Honma M, Ishida-Yamamoto A, Iizuka H. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res. 2013;305(2):113-6. doi: 10.1007/s00403-012-1310-9, PMID 23291856.

42. Zhou L, Li Y, Xia T, Feng S, Chen X, Yang Z. Resistin overexpression impaired glucose tolerance in hepatocytes. Eur Cytokine Netw. 2006;17(3):189-95. PMID 17194639.

43. Takahashi H, Tsuji H, Honma M, Ishida-Yamamoto A, Iizuka H. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res. 2013;305(2):113-6. doi: 10.1007/s00403-012-1310-9, PMID 23291856.

44. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT et al. Lipoprotein associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2523-9. doi: 10.1161/01.ATV.0000244681.72738.bc, PMID 16960105.

45. Cucchiara BL, Messe SR, Sansing L, MacKenzie L, Taylor RA, Pacelli J et al. Lipoprotein associated phospholipase A2 and C-reactive protein for risk stratification of patients with TIA. Stroke. 2009;40(7):2332-6. doi: 10.1161/STROKEAHA.109.553545, PMID 19461040.

46. Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536-44. doi: 10.1016/S0140-6736(10)60319-4.

47. Jové M, Mota-Martorell N, Pradas I, Martín-Gari M, Ayala V, Pamplona R. The advanced lipoxidation end-product malondialdehyde-lysine in aging and longevity. Antioxidants (Basel). 2020;9(11):1132. doi: 10.3390/antiox9111132, PMID 33203089.

48. Ghadge AA, Khaire AA. Leptin as a predictive marker for metabolic syndrome. Cytokine. 2019 Sep;121:154735. doi: 10.1016/j.cyto.2019.154735, PMID 31154250.

49. Buchmann N, Ittermann T, Demuth I, Markus MRP, Völzke H, Dörr M et al. Lipoprotein(a) and metabolic syndrome. Dtsch Ärztebl Int. 2022 Apr 15;119(15):270-6. doi: 10.3238/arztebl.m2022.0153, PMID 35331368.

51. Botros N, Concato J, Mohsenin V, Selim B, Doctor K, Yaggi HK. Obstructive sleep apnea as a risk factor for type 2 diabetes. Am J Med. 2009;122(12):1122-7. doi: 10.1016/j.amjmed.2009.04.026, PMID 19958890.

52. Togeiro SM, Carneiro G, Ribeiro Filho FF, Zanella MT, Santos-Silva R, Taddei JA, et al. Consequences of obstructive sleep apnea on metabolic profile: A population-based survey. Obesity (Silver Spring). 2013;21(4):847-51. doi: 10.1002/oby.20288, PMID 23712988.

Published

2023-03-01

How to Cite

kumari, D., Dr.G.Revathy, & Dr.Prabha. (2023). A Review of Inflammatory Markers in Metabolic Syndrome: Life Sciences-Medicine. International Journal of Life Science and Pharma Research, 13(Special issue 4), L159-L165. https://doi.org/10.22376/ijlpr.2023.13.2.SP2.L159-L165

Issue

Section

Review Articles